Cable Hill Partners LLC Makes New Investment in GSK PLC Sponsored ADR (NYSE:GSK)

Cable Hill Partners LLC purchased a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 6,993 shares of the pharmaceutical company's stock, valued at approximately $279,000.

Other hedge funds have also made changes to their positions in the company. Columbia Asset Management purchased a new position in GSK in the 4th quarter valued at approximately $233,000. Brighton Jones LLC purchased a new position in GSK in the 4th quarter valued at approximately $528,000. Stamos Capital Partners L.P. boosted its position in GSK by 42.3% in the 4th quarter. Stamos Capital Partners L.P. now owns 294,820 shares of the pharmaceutical company's stock valued at $9,971,000 after buying an additional 87,630 shares during the period. First Hawaiian Bank raised its holdings in shares of GSK by 18.8% in the 1st quarter. First Hawaiian Bank now owns 101,039 shares of the pharmaceutical company's stock valued at $3,914,000 after purchasing an additional 15,987 shares in the last quarter. Finally, FMR LLC lifted its position in shares of GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after purchasing an additional 23,814,104 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Performance

NYSE:GSK traded down $1.79 during mid-day trading on Thursday, reaching $36.49. The stock had a trading volume of 14,696,915 shares, compared to its average volume of 5,076,396. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. The firm has a market capitalization of $74.72 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 1.55 and a beta of 0.50. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The business has a 50 day simple moving average of $39.00 and a 200 day simple moving average of $37.34.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The firm had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter last year, the firm earned $0.43 earnings per share. The firm's revenue was up 2.1% compared to the same quarter last year. On average, analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Stockholders of record on Friday, May 16th were issued a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.62%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, May 16th. GSK's payout ratio is 88.14%.

Wall Street Analysts Forecast Growth

GSK has been the subject of several recent analyst reports. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, BNP Paribas initiated coverage on shares of GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.